A person-centred care intervention provided via eHealth to reduce fatigue in patients with common mental disorders - secondary outcome analysis from a randomized controlled trial.

Scand J Prim Health CareJul 24, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Sara Alsén, Matilda Cederberg, Andreas Fors

✦ AI-curated · Sources linked

In 30 seconds

This secondary outcome analysis from a randomized controlled trial assessed whether person-centred eHealth support reduced self-reported fatigue among 209 patients on sick leave for common mental disorders, recruited from nine Swedish primary health care centres. Participants received treatment as usual (TAU) alone or TAU plus telephone support and an interactive digital platform. At 3 and 6 months, the intervention group improved significantly more in global fatigue and in physical fatigue, reduced activity, and mental fatigue. General fatigue favoured intervention at 6 months, while reduced motivation favoured it at 3 months only. The abstract reports no effect sizes.

Key findings

  • At 3 and 6 months, global fatigue improved significantly more with the intervention than with TAU alone.
  • Physical fatigue, reduced activity, and mental fatigue improved significantly more in the intervention group at both follow-ups.
  • General fatigue favoured intervention at 6 months but not 3 months; reduced motivation favoured intervention at 3 months but not 6 months.

Why it matters

Fatigue is a relevant symptom for patients with common mental disorders who are unable to work. These findings suggest that person-centred support delivered through telephone contact and a digital platform may address several dimensions of fatigue alongside usual care. The differing results across fatigue dimensions and follow-up points underscore the importance of considering both symptom domain and timing when evaluating such interventions.

What to keep in mind

This was a secondary outcome analysis, and the abstract provides no effect sizes, limiting assessment of the magnitude of the reported differences.

Source

Published in Scand J Prim Health Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.